Caas Capital Management LP Abb Vie Inc. Call Options Transaction History

Caas Capital Management LP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $1.58 Million - $2.01 Million	11,500 New	11,500 $1.76 Million
Q1 2022 May 13, 2022	SELL	$131.98 - $163.75 $4.65 Million - $5.76 Million	-35,200 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$106.4 - $120.78 $11.7 Million - $13.3 Million	-110,000 Reduced 75.76%	35,200 $3.8 Million
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $2.61 Million - $2.91 Million	-24,800 Reduced 14.59%	145,200 $16.4 Million
Q1 2021 May 17, 2021	BUY	$102.3 - $112.62 $17.4 Million - $19.1 Million	170,000 New	170,000 $18.4 Million
Q4 2020 Feb 12, 2021	SELL	$80.49 - $108.67 $13.7 Million - $18.5 Million	-170,000 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$85.91 - $100.83 $14.6 Million - $17.1 Million	170,000 New	170,000 $14.9 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.